Nephrocheck®, which simultaneously detects TIMP-2 and IGFBP7, has been approved by the United States Food and Drug Administration as a potential aid in the prediction of moderate to severe AKI within 12 hours in critically ill patients17–19. Here, IGFBP7 is linked to acute kidney injury.